Company news
Optiscan Imaging Limited (ASX:OIL) news
Optiscan Imaging Limited news releases on 6ix. Latest, Oct 4, 2026: Optiscan Lodges U.S. FDA 510(k) Submission for InVue
Press releases & updates
Optiscan Lodges U.S. FDA 510(k) Submission for InVue
October 4, 2026
Optiscan Lodges U.S. FDA 510(k) Submission for InForm
October 1, 2026
Significant Milestone Reached in ACL Digital Pathology Study
September 9, 2026
Optiscan Initiates Head and Neck Cancer Study in the US
August 31, 2026
Preliminary Final Report
August 24, 2026
Optiscan Signs New Research Agreement for Breast Study
July 21, 2026
Head and Neck Study Progressing Ahead of Schedule
July 20, 2026
Optiscan Launches InSpecta Device for Veterinary Medicine
July 6, 2026
Halfway Mark Reached in Optiscan Breast Cancer Study
June 3, 2026
Second Anniversary of Optiscan and Mayo Clinic Agreement
May 31, 2026
Optiscan Receives $1.69m R&D Tax Refund
May 19, 2026
Optiscan Submits InSpecta FDA Dossier
March 30, 2026
Appendix 4D
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Optiscan Initiates Head & Neck Cancer Imaging Study
December 2, 2025
Optiscan Partners with ACL to Advance Digital Pathology
November 10, 2025
Appendix 4E - Preliminary Final Report
August 29, 2025
Entitlement Issue Prospectus
August 27, 2025
Optiscan Launches Entitlement Offer to Raise $17.75m
August 27, 2025
Optiscan Initiates Breast Cancer Study in Melbourne
June 30, 2025
Optiscan Signs Agreement with Long Grove Pharmaceuticals
June 22, 2025
Optiscan Reveals InSpecta Device for Veterinary Medicine
June 9, 2025
Optiscan Completes Cloud-based Telepathology Software MVP
May 26, 2025
Robotic Surgery Collaboration with Mayo Clinic Progresses
May 12, 2025
Optiscan Reveals InForm Imaging Device for Pathology
February 18, 2025
Optiscan Initiates GI Study in Germany with First Prototype
February 2, 2025
OIL December 2024 Quarterly Report and Appendix 4C
January 30, 2025
Optiscan receives $1.775m R&D Tax Refund
January 30, 2025
OIL Managing Director's Presentation & Chair's Address
November 21, 2024
Optiscan Signs Research Agreement with Minnesota Vet College
November 18, 2024
Optiscan Signs Agreement with Monash to Progress GI Scope
November 3, 2024
OIL September 2024 Quarterly Report and Appendix 4C
October 31, 2024
Appendix 4E Preliminary Final Report
August 30, 2024
Optiscan Signs MOU with University of Minnesota
August 18, 2024
OIL June 2024 Quarterly Report and Appendix 4C
July 31, 2024
Optiscan Delivers Major Milestone in Telepathology Platform
July 28, 2024
Optiscan Receives Ethical Clearance for Breast Cancer Study
July 14, 2024
Optiscan 2024 Roadshow Presentation
June 30, 2024
Optiscan Reveals InVue Imaging Device for Precision Surgery
June 3, 2024
Optiscan Webinar Investor Presentation
May 16, 2024
Optiscan Signs Know-How Agreement with Mayo Clinic
May 12, 2024
OIL March 2024 Quarterly Report and Appendix 4C
April 30, 2024
Optiscan appoints US Clinical & Regulatory Heads
April 2, 2024
OIL Appendix 4D and 31 December 2023 Half-year report
February 22, 2024
Optiscan receives $3 million CRC-P Industry Grant
February 13, 2024
OIL December 2023 Quarterly Report and Appendix 4C
January 30, 2024
Response to ASX Price Query
November 14, 2023
OIL September 2023 Quarterly Report and Appendix 4C
October 31, 2023
Optiscan Correlates with Histology in Breast Study
September 19, 2023
OIL Appendix 4E and June 2023 Annual Report
August 30, 2023